




Background



RAS mutational frequencies in cancer




RAS in mechano-regulation of cancer




How do different RAS variants impact tissue mechanics and does this lead to different tumorigenic outcomes?


Aims



Hypothesis



Workflow in *Xenopus laevis*



Key results

1. Different RAS variants produce subtly different tumours in terms of shape and cell content

A Demonstration image of how we calculated the ITLS (induced tumour-like structure) area.

B A higher mean ITLS area as a percentage of body area was observed in GFP-KrasD12-injected embryos compared to that of GFP-KrasV12-injected ones.

C Nras-mutant ITLS had a significantly higher percentage of within-tumour GFP signals relative to tumour area, when compared to KrasD12.

D Dot plot showing the mean length/width ratios of ITLS between all RAS mutant groups were not significantly different from each other. *p < 0.05, **p < 0.01, ***p < 0.001

2. Different RAS proteins have different cellular localisation

A We observed an increase of GFP+ particle number in GFP-NrasV12-injected tumour cells at stage 38 (red arrow) compared to other RAS mutants (white arrow). Scale bars are 100µm.

B Confocal images of whole-mount stained ITLS showing that NrasV12 tumours are characterized by sheets of tumour cells exhibiting epidermal morphology, while other mutants are not. Scale bars are 50µm.

3. Different RAS tumour cells might have different fates

4. Differences in early oncogenic clusters

A Bigger and centrally localised Kras mutant clusters

B Smaller and peripherally localised Nras mutant clusters

C At stage 10, in GFP-KrasD12- and GFP-NrasV12-injected embryos, the clusters were generally bigger in size and located in the centre of the animal cap (red arrow). On the contrary, in GFP-NrasK61- and GFP-NrasV12-injected embryos, the clusters were generally smaller in size and located on the edge of the animal cap (black arrow). Scale bars are 400µm.

5. Differences in signalling pathway activation downstream of RAS variants

A All RAS variants except for NrasV12 hyperactivate the MAPK pathway.

B Kras variants hyperactivate the PI3K/AKT pathway while Nras variants do not. We are currently using WB to look at the differential activation of non-muscle myosin II by RAS variants. We are also testing the effects of ERK inhibitor Ulixertinib and the AKT inhibitor Capivasertib on *Xenopus* embryos. *p < 0.05, **p < 0.01, ***p < 0.001

C We adopted laser ablation as a direct measurement of junctional mechanical tension. We used a 355nm high-power laser to physically cut the cell edge at the sites of cell-cell adhesion labelled with mCherry-CAAX. The tension could be thus visualized as the outwards recoil of the vertices following ablation. XY coordinates of the two vertices were tracked in ImageJ using the MTrackJ plugin in ImageJ and fitted to a Kelvin-Voigt model [4].

D Cropped region of confocal time-lapse stills showing laser ablation at a cell edge in a GFP-KrasV12 cluster.


E Recoil measurements.

F The initial recoil rates within KrasV12 clusters (p < 0.001), KrasD12 clusters (p < 0.01) and NrasV12 clusters (p < 0.05) were significantly higher than in GFP clusters (Kruskal-Wallis with Dunn's tests).

G K values showed no significant differences between groups (Kruskal-Wallis with Dunn's tests), suggesting that initial recoil velocity can act as an indicator of local junctional tension.


Do melanoma cells with different RAS mutations respond differently in collagen matrices with varying stiffness?

Experiments in melanoma cell lines



Conclusions

1. Subtle differences in tumour size.
2. Difference in RAS intracellular localisation.
3. Possible difference in cell fate during *Xenopus* embryos development.
4. Differential activation levels of MAPK and PI3K/AKT signalling pathways.
5. Differences in the level of contractile forces generated by cells.



Acknowledgements

Thank you to Woolner Lab, Marie Lab, Biomechanics facility and Aquatics facility. Thank you to funding through President's Doctoral Scholar Award from The University of Manchester.

References

- [1] Prior, I.A. and Hancock, J.F. (2012) 'RAS trafficking, localization and compartmentalized signalling', *Seminars in Cell & Developmental Biology*, 23(2), pp. 145-153.
- [2] Cox, A.D. et al. (2014) 'Drugging the undruggable RAS: Mission possible?', *Nature Reviews Drug Discovery*, 13(11), pp. 828-851.
- [3] Moruzzi, M. et al. (2021) 'Generation of anisotropic strain dysregulates wild-type cell division at the interface between host and oncogenic tissue', *Current Biology*, CB, 31(15), pp. 3409-3418.e6.
- [4] Fernandez-Gonzalez, Rodrigo et al. 'Myosin II dynamics are regulated by tension in intercalating cells.' *Developmental cell* vol. 17,5 (2009): 736-43.
- [5] hmadzadeh H, Webster MR, Behera R, et al. Modeling the two-way feedback between contractility and matrix realignment reveals a nonlinear mode of cancer cell invasion. *Proc Natl Acad Sci U S A*. 2017;114(9):E1617-E1626. doi:10.1073/pnas.1617037114